Hospitals & Healthcare Pressreleases

This section covers the managerial aspects in the Healthcare industry.

CORRECTING and REPLACING Quintiles Officially Opens Greater China Regional Headquarters in Shanghai

Sunday, May 31, 2015
Bussinesswire

SHANGHAIBUSINESS WIRE Third paragraph of release dated May 29 2015 should read Vice District Mayor Wang Hongzhou of Xuhui District Shanghai joined Dr Gillings in speaking at the opening Instead of Vice District Mayor Wang Hongzhou of Xihui District Shanghai joined Dr Gilli..

Zydelig® in Combination With Ofatumumab Improves Progression-Free Survival in Previously-Treated Patients With Chronic Lymphocytic Leukemia

Sunday, May 31, 2015
Bussinesswire

CHICAGOBUSINESS WIRE Gilead Sciences Inc NasdaqGILD today announced results from the Phase 3 clinical Study 119 of an investigational use of Zydelig idelalisib in combination with ofatumumab in previouslytreated patients with chronic lymphocytic leukemia CLL In Study 119 t..

Amgen Initiates Phase 3 Study Evaluating Once-Weekly Kyprolis® (carfilzomib) in Patients With Relapsed And Refractory Multiple Myeloma

Sunday, May 31, 2015
PR Newswire

THOUSAND OAKS Calif May 31 2015 PRNewswire Amgen NASDAQAMGN today announced the initiation of the ARROW trial a global Phase 3 study evaluating the benefit of Kyprolis carfilzomib for Injection administered onceweekly with dexamethasone versus the current US Food and Drug Administration FDA approv..

Study finds changes in treatment have increased life span for childhood cancer survivors

Sunday, May 31, 2015
PR Newswire

CHICAGO May 31 2015 PRNewswire Evidence from the Childhood Cancer Survivor Study suggests that changes in childhood cancer treatment have reduced deaths from the late effects of cancer treatment and extended the lives of childhood cancer survivors St Jude Childrens Research Hospital investigators..

AbbVie Presents Results from Phase 1 Studies of Investigational Compound Venetoclax in Patients with Multiple Myeloma at the American Society of Clinical Oncology Annual Meeting

Sunday, May 31, 2015
PR Newswire

NORTH CHICAGO Ill May 31 2015 PRNewswire AbbVie NYSEABBV a global biopharmaceutical company today announced that results from a Phase 1b trial of investigational venetoclax a novel inhibitor of the Bcell lymphoma2 BCL2 protein that is being developed in partnership with Genentech and Roche in comb..

Caris Life Sciences Presents New Tumor Profiling Research Providing Insights into the Clinical Benefit of Targeted Therapies for Colorectal Cancer Treatment-Resistant Subgroups

Sunday, May 31, 2015
PR Newswire

IRVING Texas May 31 2015 PRNewswire Caris Life Sciences a leading biotechnology company focused on fulfilling the promise of precision medicine today announced the results of a study identifying the clinical benefit of targeted therapy in colorectal cancer CRC with high microsatellite instability..

Analysis of Phase III RESONATE™ Data Shows Adherence to the Recommended 420mg Dose of IMBRUVICA® (ibrutinib) Results in Improved Efficacy Benefits in Patients with Chronic Lymphocytic Leukemia

Sunday, May 31, 2015
PR Newswire

SUNNYVALE Calif May 31 2015 PRNewswire Pharmacyclics LLC today highlighted results from a subanalysis of the Phase III RESONATE PCYC1112 trial which found that previouslytreated patients with chronic lymphocytic leukemia CLL who adhered to the recommended 420 mg dose of IMBRUVICA ibrutinib experi..

Ibrutinib (IMBRUVICA®) Phase Ib/II Data Show Promise in Patients with Chronic Graft-Versus-Host-Disease

Sunday, May 31, 2015
PR Newswire

SUNNYVALE Calif May 31 2015 PRNewswire Pharmacyclics LLC today announced interim results from the ongoing Phase IbII PCYC1129 study suggesting that ibrutinib IMBRUVICA may be a safe and effective treatment for patients with chronic graftversushostdisease cGVHD who were either refractory to steroi..

ASCO 2015: Superior overall survival for afatinib compared to erlotinib demonstrated in head-to-head trial in patients with previously treated advanced squamous cell carcinoma of the lung

Sunday, May 31, 2015
PR Newswire

RIDGEFIELD Conn May 31 2015 PRNewswire Boehringer Ingelheim today announced overall survival OS results from the LUXLung 8 trial NCT01523587 that directly compared the efficacy and safety of two EGFRdirected treatments afatinib and erlotinib in patients with advanced squamous cell carcinoma SCC of..

Combination of Novartis drugs Tafinlar® and Mekinist® shows significant survival benefit in patients with metastatic melanoma

Sunday, May 31, 2015
PR Newswire

EAST HANOVER NJ May 31 2015 PRNewswire Novartis today announced data from the Phase III COMBId study showing a significant survival benefit for patients with BRAF V600EK mutationpositive metastatic melanoma when treated with the combination of Tafinlar dabrafenib and Mekinist trametinib compared ..

Halozyme Phase 2 Clinical Study Of Investigational Drug PEGPH20 Shows Doubling Of Progression-free Survival And Improvement Trend In Overall Survival In High HA Metastatic Pancreatic Cancer Patients

Sunday, May 31, 2015
PR Newswire

SAN DIEGO May 31 2015 PRNewswire Halozyme Therapeutics Inc NASDAQ HALO a biotechnology company developing novel oncology and drugdelivery therapies today announced interim findings from the ongoing phase 2 clinical study of its investigational new drug PEGPH20 for the potential treatment of patie..

PharmaEngine Announces Filing New Drug Application (NDA) of MM-398 (PEP02) to Taiwan FDA as a Treatment for Post-Gemcitabine Metastatic Pancreatic Cancer

Sunday, May 31, 2015
PR Newswire

TAIPEI May 31 2015 PRNewswire PharmaEngine Inc TWO4162 today announced that a New Drug Application NDA has been submitted to the Taiwan Food and Drug Administration TFDA for MM398 irinotecan liposome injection also known as nalIRI in patients with metastatic adenocarcinoma of the pancreas who..

First UnitedHealthcare IRONKIDS® Raleigh Fun Run Motivates Local Youth to Lead Active, Healthy Lifestyles

Saturday, May 30, 2015
Bussinesswire

RALEIGH NCBUSINESS WIRE More than 200 youth participated in the first UnitedHealthcare IRONKIDS Raleigh Fun Run today UnitedHealthcare mascot Dr Health E Hound kickedoff the fun run joined by Anita Bachmann of UnitedHealthcare and County Commissioners Caroline Sullivan and..

Clovis Oncology’s Phase 2 Studies of Rucaparib in Ovarian Cancer Demonstrate Highly Compelling Clinical Activity, in Both BRCA-mutant and BRCA-like Patients, Together Comprising Approximately 60 Percent of Patients

Saturday, May 30, 2015
Bussinesswire

CHICAGOBUSINESS WIRE Clovis Oncology NASDAQCLVS today announced updated Phase 2 results from two ongoing clinical studies with rucaparib ARIEL2 and Study 10 Rucaparib is the Companys investigational oral potent small molecule inhibitor of PARP1 and PARP2 being developed fo..

Studies Presented at 2015 ASCO Meeting Demonstrate Predictive Power of bioTheranostics’ Breast Cancer Index? Molecular Test in Endocrine Therapy Decisions

Saturday, May 30, 2015
Bussinesswire

CHICAGOBUSINESS WIRE bioTheranostics Inc today announced results from studies being presented at the 2015 American Society of Clinical Oncology ASCO meeting reinforcing the role its Breast Cancer IndexSM BCI molecular test plays in informing decisions about extendin..

Phase 3 Trial Investigating Eribulin in Patients with Advanced Soft Tissue Sarcoma Demonstrated Improved Overall Survival

Saturday, May 30, 2015
PR Newswire

WOODCLIFF LAKE NJ May 30 2015 PRNewswire Eisai Inc announced today the results of its Phase 3 trial Study 309 which showed that eribulin met the studys primary endpoint evaluating overall survival in patients who had advanced leiomyosarcoma LMS or adipocytic sarcoma ADI two types of advanced soft ..

Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015

Saturday, May 30, 2015
PR Newswire

CHICAGO May 30 2015 PRNewswire CTI BioPharma Corp CTI BioPharma NASDAQ and MTA CTIC and Baxter Internationals Bioscience business NYSEBAX today announced data from PERSIST1 a randomized Phase 3 registrationdirected trial examining pacritinib for the treatment of myelofibrosis in a latebreaking ..

Phase III HELIOS Study Results Show Ibrutinib (IMBRUVICA®) Combination Therapy Significantly Increased Progression-Free Survival in Previously-Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Patients

Saturday, May 30, 2015
PR Newswire

CHICAGO May 30 2015 PRNewswire Today Pharmacyclics LLC announced the results of the Phase III HELIOS trial CLL3001 which found that patients with previously treated chronic lymphocytic leukemia CLL or small lymphocytic lymphoma SLL who received ibrutinib IMBRUVICA in combination with bendamustine ..

Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients

Saturday, May 30, 2015
PR Newswire

CHICAGO and RARITAN NJ May 30 2015 PRNewswire Data from the international multicenter openlabel twopart singlearm Phase 2 MMY2002 SIRIUS trial show treatment with singleagent daratumumab an investigational human antiCD38 monoclonal antibody achieved an overall response rate ORR of 292 percent 95..

Ibrutinib (IMBRUVICA®) HELIOS Interim Analysis Study Data Show Significant Reductions in Risk of Progression or Death in Patients with Previously-Treated Chronic Lymphocytic Leukemia

Saturday, May 30, 2015
PR Newswire

CHICAGO and RARITAN NJ May 30 2015 PRNewswire Data from the Phase 3 CLL3001 HELIOS trial demonstrated that the combination of ibrutinib IMBRUVICA plus bendamustine and rituximab BR reduced the risk of progression or death by 80 and also significantly improved overall response rate ORR versus place..

TOP